Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry-Reference-Cited by-同舟云学术

Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry

Published:2024-09-01 Issue:3 Volume:19 Page:99-111
ISSN:2413-4023
Container-title:Oncohematology
language:
Short-container-title:Onkogematologiâ

Author:

Tolstykh T. N.¹^ORCID,Misyurina E. N.¹^ORCID,Mingalimov M. A.¹^ORCID,Baryakh E. A.²^ORCID,Zhelnova E. I.¹^ORCID,Gagloeva D. E.¹^ORCID,Kardovskaya S. A.³^ORCID,Chudnova T. S.¹^ORCID,Zotina E. N.¹^ORCID,Ivanova D. D.³^ORCID,Kochneva O. L.³^ORCID,Yatskov K. V.³^ORCID,Shimanovskaya L. T.³^ORCID,Mar’in D. S.³,Makeshova A. B.¹^ORCID,Chernova N. G.⁴^ORCID,Dudina G. A.⁵^ORCID,Granatkin M. A.⁶^ORCID,Semina T. A.⁷^ORCID,Misyurin A. V.⁸^ORCID,Lysenko M. A.³^ORCID

Affiliation:

1. City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

2. City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department

3. City Clinical Hospital No. 52, Moscow Healthcare Department

4. Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department

5. A.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department

6. S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department

7. Moscow Healthcare Department

8. Vavilov Institute of General Genetics, Russian Academy of Sciences

Abstract

Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on Moscow permanent residents who were primary diagnosed with AML from January 2019 to November 2023. The effectiveness of antitumor therapy was assessed by the complete remissions rate, relapses, deaths, and 3-year overall and relapse-free survival. Data analysis performed as of 01.12.2023.Results. According to the Moscow Cancer Registry, from 01.01.2019 to 01.12.2023, the diagnosis of AML (except for acute promyelocytic leukemia) was established in 752 patients with a median age at the time of diagnosis of 64 (19– 94) years. In the studied sample, females slightly predominated: women – 56.6 % (n = 426), men – 43.4 % (n = 326). Of all patients included in the study, 36 % (n = 275) received intensive chemotherapy, while 57 % (n = 427) received low-intensity chemotherapy, and the remaining 7 % (n = 50) patients received best supportive care. Early mortality (first 60 days) in the total group was 16 % (n = 123), 20 % (n = 149) of patients were refractory to the therapy. Complete remission was achieved by 63 % (n = 473) of patients: 82 % (n = 225) of them received intensive chemotherapy, 58 % (n = 248) – low-intensity chemotherapy. Relapses occurred in 41 % (n = 194) of 473 patients who achieved complete remission. In the first remission, allogeneic hematopoietic stem cell transplantation was performed in 11 % (n = 79) of patients. With a median follow-up of 30.1 months, the 3-year overall survival in total group was 27 % (95 % confidence interval 23–32), and the 3-year relapse-free survival was 44 % (95 % confidence interval 37–51).Conclusion. The main problem in the treatment of adult AML patients remains high induction mortality and limited opportunities for allogeneic hematopoietic stem cell transplantation in real clinical practice, which emphasizes the need to develop transplant centers in Moscow.

Publisher

Publishing House ABV Press

Reference27 articles.

1. Afanas’ev B.V., Baranova O.Yu., Bondarenko S.N. et al. Clinical guidelines “Acute myeloid leukemia”. Moscow: Ministry of Health of Russia, 2020. 87 p. Available at: https://cr.minzdrav.gov.ru/ recomend/131_1 (In Russ.).

2. Short N.J., Rytting M.E., Cortes J.E. Acute myeloid leukaemia. Lancet 2018;392(10147):593–606. DOI: 10.1016/S0140-6736(18)31041-9

3. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).

4. Semochkin S.V., Tolstykh T.N., Arkhipova N.V. et al. Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow. Terapevticheskiy arkhiv = Therapeutic Archive 2015;87(7):26–32. (In Russ.). DOI: 10.17116/terarkh201587726-32

5. Döhner H., Wei A., Appelbaum F. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140(12):1345–77. DOI: 10.1182/blood.202201686